These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 28411455)

  • 21. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
    J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
    Zhan Z; Peng X; Liu Q; Chen F; Ji Y; Yao S; Xi Y; Lin Y; Chen T; Xu Y; Ai J; Geng M; Duan W
    Eur J Med Chem; 2016 Jun; 116():239-251. PubMed ID: 27061987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
    Cui JJ; Shen H; Tran-Dubé M; Nambu M; McTigue M; Grodsky N; Ryan K; Yamazaki S; Aguirre S; Parker M; Li Q; Zou H; Christensen J
    J Med Chem; 2013 Sep; 56(17):6651-65. PubMed ID: 23944843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Progress in the Development of Small Molecule c-Met Inhibitors.
    Lv PC; Yang YS; Wang ZC
    Curr Top Med Chem; 2019; 19(15):1276-1288. PubMed ID: 31526339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
    Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
    Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Patents on the Development of c-Met Kinase Inhibitors.
    Xu X; Yao L
    Recent Pat Anticancer Drug Discov; 2020; 15(3):228-238. PubMed ID: 32603284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization techniques for novel c-Met kinase inhibitors.
    Sun ZG; Yang YA; Zhang ZG; Zhu HL
    Expert Opin Drug Discov; 2019 Jan; 14(1):59-69. PubMed ID: 30518273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tepotinib: First Approval.
    Markham A
    Drugs; 2020 Jun; 80(8):829-833. PubMed ID: 32361823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways.
    Martorana A; La Monica G; Lauria A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32961977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinoline as a privileged scaffold in cancer drug discovery.
    Solomon VR; Lee H
    Curr Med Chem; 2011; 18(10):1488-508. PubMed ID: 21428893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Have Clinical Trials Properly Assessed c-Met Inhibitors?
    Hughes VS; Siemann DW
    Trends Cancer; 2018 Feb; 4(2):94-97. PubMed ID: 29458966
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.